What are the preventative medication options for sexually transmitted infections (STIs)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Preventative Medication Options for Sexually Transmitted Infections (STIs)

Doxycycline post-exposure prophylaxis (DoxyPEP) is recommended for high-risk populations, particularly cisgender men who have sex with men and transgender women, taken as a 200 mg single dose within 72 hours after condomless sex to prevent bacterial STIs. 1

HIV Prevention Options

Pre-Exposure Prophylaxis (PrEP)

  • Daily oral TDF/FTC (tenofovir disoproxil fumarate/emtricitabine) remains the recommended oral PrEP regimen for all populations at risk of HIV exposure (evidence rating: A1a) 1
  • PrEP should be discussed and offered to:
    • All sexually active persons
    • Anyone requesting PrEP
    • People who inject drugs or use substances
    • Populations with high HIV incidence rates 1
  • Long-acting cabotegravir is an injectable PrEP option with follow-up monitoring using rapid HIV antibody and laboratory-based antigen/antibody tests 1

Post-Exposure Prophylaxis (PEP)

  • For individuals with known exposure to HIV
  • Must be started within 72 hours of exposure
  • Typically involves a 28-day course of antiretroviral medications 1

Bacterial STI Prevention

Doxycycline Post-Exposure Prophylaxis (DoxyPEP)

  • Dosing: 200 mg taken as a single dose within 72 hours after condomless sex 1
  • Effectiveness:
    • Reduces syphilis and chlamydia infections by >70%
    • Reduces gonococcal infections by approximately 50% 2
  • Recommended populations:
    • Cisgender men who have sex with men (MSM)
    • Transgender women (TGW)
    • Individuals with HIV (regardless of status) 1
    • Case-by-case basis for cisgender women at risk (based on pharmacokinetic modeling) 1
  • Prescription guidance: Provide 30 doses (60 tablets/capsules) at a time 1
  • Monitoring: Quarterly STI screening of contact sites and blood syphilis testing 1

Prophylaxis After Sexual Assault

  • Recommended regimen:
    • Ceftriaxone 125 mg IM (single dose)
    • Metronidazole 2 g orally (single dose)
    • Azithromycin 1 g orally (single dose) OR Doxycycline 100 mg orally twice daily for 7 days 1, 2
  • Hepatitis B vaccination should be administered at initial examination with follow-up doses at 1-2 and 4-6 months 1, 2

Viral STI Prevention

Hepatitis B

  • Vaccination is the primary preventive measure 1
  • Recommended for all unvaccinated patients being evaluated for an STD 1

Hepatitis A

  • Vaccination recommended for:
    • Men who have sex with men
    • Persons who use illegal drugs 1

HPV

  • HPV vaccination is recommended as part of comprehensive STI prevention 2

Important Considerations and Monitoring

For DoxyPEP

  • Potential side effects: Photosensitivity, esophagitis, gastrointestinal intolerance 1, 2
  • Administration guidance: Take with food and plenty of fluid, remain upright for at least 1 hour after taking 2
  • Drug interactions: Separate dose by at least 2 hours from dairy products, antacids, and supplements containing calcium, iron, magnesium, or sodium bicarbonate 1
  • Reassessment: Evaluate ongoing need for DoxyPEP every 3-6 months 1, 2

For PrEP

  • Baseline testing: HIV screening including RNA test and laboratory-based antigen-antibody test 1
  • Follow-up: Regular HIV testing and STI screening every 3-6 months 1
  • Renal monitoring: TDF-based PrEP is not recommended in persons with creatinine clearance below 60 mL/min/1.73m² 1

Comprehensive Prevention Approach

  • Condom use remains a cornerstone of prevention for all penetrative sex acts (evidence rating: AIII) 1
  • Regular STI screening at anatomic sites of exposure every 3-6 months 1, 2
  • Risk reduction counseling should accompany all preventative medication strategies 1, 2

Common Pitfalls and Caveats

  1. Antimicrobial resistance concerns: The benefit of DoxyPEP in preventing STIs must be weighed against potential development of antimicrobial resistance 3

  2. Limited evidence in certain populations: DoxyPEP efficacy data is strongest for MSM and transgender women; evidence for cisgender women is limited 3

  3. Medication adherence: Effectiveness of preventative medications depends on proper adherence to prescribed regimens 1

  4. False sense of security: Preventative medications should not replace other STI prevention strategies like condom use 1, 2

  5. Viral STIs limitations: Current preventative medications primarily target bacterial STIs and HIV; limited options exist for preventing herpes simplex, human papillomavirus, and other viral STIs 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

STD Prevention and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.